Modulation of Activity of Neurotrophins
US-2017158766-A1 · Jun 8, 2017 · US
Peptides derived from the propeptide NTSR3 and their use in the treatment of depression
US11220527B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11220527-B2 |
| Application number | US-201716340832-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 11, 2017 |
| Priority date | Oct 11, 2016 |
| Publication date | Jan 11, 2022 |
| Grant date | Jan 11, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed are new peptides derived from the neurotensin receptor 3 (NTSR3), and to their use, particularly in the treatment of various diseases, especially depression.
First claim
Opening claim text (preview).
The invention claimed is: 1. A peptide derived from the propeptide (PE) of the neurotensin receptor 3 (NTSR3) selected from the group consisting of: the peptide G/A-PE(22-28) consisting of the amino acid sequence of SEQ ID NO: 7 (AVSWGLR), and the biotinylated peptide G/A-PE(22-28) corresponding to the sequence SEQ ID NO: 7 biotinylated. 2. A medicament comprising the peptide according to claim 1 . 3. The medicament according to claim 2 , wherein the medicament is an antidepressant. 4. A method for treating depression in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of the peptide according to claim 1 .
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11220527B2 cover?
- Disclosed are new peptides derived from the neurotensin receptor 3 (NTSR3), and to their use, particularly in the treatment of various diseases, especially depression.
- Who is the assignee on this patent?
- Centre Nat Rech Scient, Univ De Nice—Sophia Antipolis, Univ Nice Sophia Antipolis
- What technology area does this patent fall under?
- Primary CPC classification C07K7/06. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).